Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both
| Autor: | Richard Hafner, Charles van der Horst, Robert L. Murphy, Thomas M. Hooton, Henry H. Balfour, Wafaa El-Sadr, Roberta Luskin-Hawk, Thomas Kerkering, Tony W. Cheung, Teresa Yurik, Robert H.K. Eng, Malte Schutz |
|---|---|
| Rok vydání: | 1998 |
| Předmět: | |
| Zdroj: | New England Journal of Medicine. 339:1889-1895 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejm199812243392604 |
| Popis: | Background Although trimethoprim–sulfamethoxazole is the drug of choice for the prevention of Pneumocystis carinii pneumonia, many patients cannot tolerate it and must switch to an alternative agent. Methods We conducted a multicenter, open-label, randomized trial comparing daily atovaquone (1500-mg suspension) with daily dapsone (100 mg) for the prevention of P. carinii pneumonia among patients infected with the human immunodeficiency virus who could not tolerate trimethoprim–sulfamethoxazole. The median follow-up period was 27 months. Results Of 1057 patients enrolled, 298 had a history of P. carinii pneumonia. P. carinii pneumonia developed in 122 of 536 patients assigned to atovaquone (15.7 cases per 100 person-years), as compared with 135 of 521 in the dapsone group (18.4 cases per 100 person-years; relative risk for atovaquone vs. dapsone, 0.85; 95 percent confidence interval, 0.67 to 1.09; P=0.20). The relative risk of death was 1.07 (95 percent confidence interval, 0.89 to 1.30; P=0.45), and the r... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|